[{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"691969a6-dc3e-4580-99bb-0a9ff4f0cef1","acronym":"NIRADO","url":"https://clinicaltrials.gov/study/NCT04779151","created_at":"2021-03-03T13:57:08.218Z","updated_at":"2024-07-02T16:35:12.913Z","phase":"Phase 2","brief_title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","source_id_and_acronym":"NCT04779151 - NIRADO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 51","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-03-26"},{"id":"6a7cc96b-1a8d-4c60-a5b9-6a9e7c5f86aa","acronym":"NBIBLI","url":"https://clinicaltrials.gov/study/NCT03748667","created_at":"2021-08-02T20:53:11.763Z","updated_at":"2024-07-02T16:35:36.493Z","phase":"","brief_title":"Accuracy for Predicting Deep Submucosal Invasion","source_id_and_acronym":"NCT03748667 - NBIBLI","lead_sponsor":"Althaia Xarxa Assistencial Universitària de Manresa","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4"],"overall_status":"Completed","enrollment":" Enrollment 426","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 10/30/2022","study_completion_date":" 10/30/2022","last_update_posted":"2023-09-21"},{"id":"c66f765b-84b8-4be7-b6e5-f176047b0b9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04633902","created_at":"2021-01-19T20:37:04.111Z","updated_at":"2024-07-02T16:35:59.576Z","phase":"Phase 2","brief_title":"Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation","source_id_and_acronym":"NCT04633902","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation","tags":["BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRAF mutation • BRAF V600 • ATM mutation • ARID1A mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-06"},{"id":"eb1cce54-97f6-48d4-8e71-c0f921263e6a","acronym":"CPMC17-MEL01","url":"https://clinicaltrials.gov/study/NCT03925350","created_at":"2021-01-18T19:18:35.366Z","updated_at":"2025-02-25T13:18:57.286Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation","source_id_and_acronym":"NCT03925350 - CPMC17-MEL01","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • ATRX • BRCA • CHEK2 • RAD51 • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B","pipe":" | ","alterations":" ATM mutation • ARID1A mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRAF • BRCA1 • BRCA2 • ARID1A • BAP1 • ATRX • BRCA • CHEK2 • RAD51 • BRIP1 • RAD50 • ARID2 • BARD1 • FANCD2 • RAD54B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2021-10-22"}]